CAUTIONARY NOTE TO READERS OF CUBA BUSINESS REPORT RE CUBAN INTERFERON “EFFECTIVE”

A memorandum listing the danger to patients contracting COVID-19 virus who are treated with interferon was sent to Cuba Business Report through its “Contact Us” portal on April 18, 2020, at 4.45 PM. The purpose of the memo was to describe CBR’s column "Cuba’s Interferon Alfa 2b Demonstrates Effectiveness against COVID-19" as knowingly irresponsible reporting of fabricated information that demonstrably has the prospect of increasing morbidity in patients with the disease and increasing mortality.

The memorandum lists just four of numerous reports vigorously cautioning against the use of interferon for the treatment of COVID-19.
 

For readers of this cautionary note here are a sufficient number of the leading sources of information for conviction that even a superficial search by Cuba Business Report would have surfaced:
 

  1. American Medical Association Journal – April 16, 2020 – “Pharmacologic Treatments for Coronavirus Disease 2019.”

  2. Ziegler, C (Harvard); Allon,S (MIT) – “SARS- CoV-2 receptor ACE 2 is an interferon-stimulated gene in human airway epithelial cells…” Avoid interferon

  3. Canada’s BC Centre for Disease Control – April 12, 2020 – “unproven therapies for COVID 19” – interferon contraindicated

  4. https://www.CubanBiotec.com/– “Cuban Interferon – Hyperbole in a time of society-devastating plague.”
     

The memorandum to CBR cautioned it that patients or their families where interferon has increased morbidity or led to death, may wish to consider recompense from CBR for its knowingly distributing dangerous and materially-misleading information.